The classical biomarkers for a patient decision of treatment immunotherapies include PD-L1 immune cell status, TMB, and tumor-infiltrating T cells, as S1 subtype samples were correlated with a high level of tumor-infiltrating T cells (Figure 3A) and TMB (Supplementary Figure 2B) immune score (Supplementary Figure 3A). The gene discussed is CD274; the disease is neoplasm.